Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Oncology societies already grade how much benefit each new drug gives. Payers should tie the maximum price they pay to that grade.
The ESMO Magnitude of Clinical Benefit Scale and ASCO Value Framework grade drugs by survival gain, quality of life and toxicity, but prices bear little relation to the grades; several analyses find no correlation between price and benefit. The proposal is for a coalition of public payers to publish a price corridor per benefit tier (for example a multiple of GDP per capita per life-year gained for grade 4-5 versus a much lower ceiling for grade 1-2) and to make the tier a binding input to negotiation, with prices revisited when confirmatory data change the grade.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
Pages like this
not linked directly; found by shared links- IdeaLaunch prices indexed to the ESMO benefit scale, revisited when survival matures
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaBundled episode payments for cancer care with bonuses for guideline concordance
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaMicro-learning pushed to community oncologists within 30 days of a practice change
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO).
- IdeaPay a different price for the same cancer drug depending on the indication
Shares European Society for Medical Oncology (ESMO), Prices and value.
- IdeaA public equity index for trial sites and sponsors, tied to funding
Shares American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains.
- IdeaDisclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaPay oncologists for the time it takes to enrol a patient
Shares American Society of Clinical Oncology (ASCO), Incentives reward me-too drugs and marginal gains.
- IdeaGive negative trials plenary slots at the big cancer conferences
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO).